Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AB Science SA announces initiation of a new phase 3 study in oncology with masitinib in patients with metastatic colorectal cancer


Monday, 2 Dec 2013 12:00pm EST 

AB Science SA:Says it has initiated a phase 3 study to evaluate the safety and efficacy of masitinib in combination with FOLFIRI in patients with metastatic colorectal cancer (mCRC) in first relapse.Says this is a study to evaluate the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) for second-line treatment of patients with metastatic colorectal cancer.Says the study will measure overall survival as a primary efficacy criterion.Says one of the objectives of this phase 3 study in colorectal cancer will be to identify those subgroups that best respond to masitinib. 

Company Quote

9.45
0.19 +2.05%
5:13am EDT